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Increasing diagnosis of cancer when the disease is still at early stages is a priority of cancer policy internationally. In 40 
England, reducing geographical inequalities in early diagnosis is also a key objective. Stage at diagnosis is not 41 
recorded for many patients, which may bias assessments of progress. We evaluate temporal and geographical 42 
changes in stage at diagnosis during 2008-2013 for colorectal, non-small cell lung, and ovarian cancers, using 43 
multiple imputation to minimise bias from missing data. 44 
 45 
Methods 46 
Population-based data from cancer registrations, routes to diagnosis, secondary care, and clinical audits were 47 
individually linked. Patient characteristics and recorded stage were summarised. Stage was imputed where missing 48 
using auxiliary information (including patient's survival time). Logistic regression was used to estimate temporal and 49 
geographical changes in early diagnosis adjusted for case mix using a multilevel model. 50 
 51 
Results 52 
We analysed 196,511 colorectal, 180,048 non-small cell lung, and 29,076 ovarian cancer patients. We estimate that 53 
there were very large increases in the percentage of patients diagnosed at stages I or II between 2008-09 and 2012-54 
13: from 32% to 44% for colorectal cancer, 19% to 25% for non-small cell lung cancer, and 28% to 31% for ovarian 55 
cancer. Geographical inequalities reduced for colorectal and ovarian cancer. 56 
 57 
Interpretation 58 
Multiple imputation is an optimal approach to reduce bias from missing data, but residual bias may be present in 59 
these estimates. Increases in early-stage diagnosis coincided with increased diagnosis through the "two week wait" 60 
pathway and colorectal screening. Epidemiological analyses from 2013 are needed to evaluate continued progress.  61 
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1. INTRODUCTION 62 
Diagnosis of cancer when the disease is still at an early stage is associated with markedly improved survival 63 
prospects [1, 2]. Increasing the proportion of patients diagnosed at early stages (often defined as stages I or II) is a 64 
focus of cancer policy in the UK and internationally [3-9].  65 
In England, increased early diagnosis has been identified as one means to reduce the survival gap with other affluent 66 
countries [10]. Numerous early diagnosis targets and interventions have been initiated. In 2000 a target was 67 
introduced that no patient should have more than a two-week wait (2WW) to see a cancer specialist following 68 
general practitioner (GP) referral with possible cancer symptoms [7]. From 2007 that target was extended to include 69 
patients referred from a hospital or through screening [11]. In 2005 national guidance for GPs on referring patients 70 
with possible cancer symptoms to specialists was published [12]. Faecal Occult Blood Test (FOBT) screening for 71 
colorectal cancer was rolled out nationally during 2006-2009 [13], and from 2011 the ‘Be Clear on Cancer’ campaign 72 
has raised awareness of the symptoms from common and rarer cancers, and encouraged people to report them to 73 
their GP [14]. In 2015 it became national policy that by 2020 62% of staged cancers should be diagnosed at stages I 74 
or II; that the proportion of cancers staged should increase; and that inequalities between the local healthcare 75 
commissioners (Clinical Commissioning Groups - CCGs) should decrease [3].  76 
To monitor progress against these targets, from 2016 Public Health England have produced a public-facing website 77 
of cancer statistics, the CancerData dashboard [15]. The dashboard presents the percentage of cancers with the 78 
disease stage recorded, and the percentage of those diagnosed at stages I or II, nationally and for each CCG, for each 79 
year from 2012. This “stages I or II” percentage is needed to monitor progress against the target set in 2015. 80 
However, it may be biased if used for analyses of changes in stage in the whole population, as it excludes patients 81 
whose stage was not ascertained or not collected centrally. Nationally, stage recording increased dramatically from 82 
2008 but still only covered 71% of patients in 2013 [15]. The patients without recorded stage have poorer outcomes 83 
than patients with stage recorded, suggesting a less favourable underlying stage distribution [16, 17].  84 
In addition to missing data, a consideration when interpreting stage trends is the extent to which observed changes 85 
are due changes in health services, for example the introduction of a screening programme, or patient case mix, such 86 
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as a decrease in the incidence of hard-to-detect tumours. Case-mix differences have been found to confound CCG 87 
rankings of early-stage diagnosis [18], and may also influence temporal comparisons. 88 
In this study we analyse temporal and geographic differences in stage at diagnosis during 2008-2013, using statistical 89 
techniques to account for missing data and case mix differences. We analyse three malignancies commonly 90 
diagnosed late: colorectal cancer, non-small cell lung cancer (NSCLC), and ovarian cancer. We evaluate whether the 91 
number of patients diagnosed at stages I or II increased; whether geographic inequalities increased or decreased; 92 
and whether observed changes are associated with case-mix. Multiple imputation is employed to minimise bias from 93 
missing stage data [19-21]. 94 
 95 
2. MATERIALS AND METHODS 96 
2.1 Data  97 
Data on cancer registrations were obtained from the Office for National Statistics (ONS) for adults aged 15–99 years, 98 
diagnosed with colorectal cancer, NSCLC or ovarian cancer in England from 1 January 2008 to 31 December 2013 99 
(ICD-10 codes C18-20, C21.8; C33-34; and C56-C57.7 [22]). Data on patient’s vital status was complete up to 31 100 
December 2014. Data were additionally linked to the national bowel and lung cancer audit datasets [23, 24], the 101 
Routes to Diagnosis (RtD) dataset [25], and Hospital Episodes Statistics (HES) records using patient’s NHS number 102 
and postcode. The audit datasets were used to gain additional information on stage [26], whilst RtD records 103 
provided information about patient’s interactions with the National Health Service (NHS) before diagnosis. The HES 104 
records provided information on receipt of major surgical treatment following diagnosis (based on OPCS 105 
Classification for Interventions and Procedures version 4 codes; full list in appendices) and Charlson Comorbidity 106 
Index (CCI - derived from HES records from 6 to 60 months prior to cancer diagnosis) [27].  107 
Clinical Commissioning Group (CCG) areas were used to examine geographical inequalities. These territories were 108 
chosen as they have been responsible for commissioning cancer services from 2013, following the dissolution of the 109 
Primary Care Trusts which were previously responsible for cancer treatment. Differences in the proportion of 110 
patients diagnosed at an early stage were compared between three time periods: 2008-09, 2010-11, and 2012-13. 111 
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Two-year periods were chosen to ensure each had sufficient numbers of patients for a robust comparison of 112 
geographic inequalities.  113 
 114 
2.2 Descriptive analysis 115 
Temporal changes in the distribution of stage at diagnosis (I, II, III, IV, or missing) were evaluated. The percentage of 116 
patients diagnosed at stage I or II (of those with a recorded stage) was tabulated by patient characteristics. The 117 
association between each characteristic and missing stage was assessed.  118 
 119 
2.3 Multiple imputation 120 
Multiple imputation was conducted to estimate patient’s stage of disease at diagnosis where unknown [28]. 121 
Imputation models including auxiliary patient information were fitted with the R package jomo [29], which accounts 122 
for the multi-level structure of the data (patients clustered within CCGs). It was assumed that stage was missing 123 
randomly conditional on variables strongly associated with either stage (I to IV) [16, 30-32], or with recording of 124 
stage [17]: quarter year of diagnosis, cancer registry area, CCG, age, sex, patient’s Indices of Multiple deprivation 125 
(IMD) income quintile, Charlson comorbidity score, tumour topography, tumour morphology, route to diagnosis, 126 
receipt of major surgical treatment (yes/no), treatment admission method (elective/non-elective), time from 127 
diagnosis to censoring, and vital status at censoring. Cancer registry area of diagnosis was included as well as CCG, as 128 
historically the regional registries recorded stage at different levels of completeness for different tumours.  129 
Tumour morphology and topography included categories which were uninformative as to the actual values (“non-130 
specific”, “miscellaneous and unspecified”). These values were re-coded to true missing and imputed using jomo 131 
alongside missing stage.  132 
The number of imputation datasets created was equal to the percentage of missing data for each cancer: 39, 20, and 133 
41 respectively for colorectal cancer, NSCLC, and ovarian cancer. These numbers are sufficient to achieve a <1% 134 
power reduction compared to using n=100 datasets [33]. Parameter estimates (percentages of patients at different 135 
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stages, and regression model parameters) were produced using each dataset and combined using Rubin’s rules [34]. 136 
Full details of the imputation and examples of the R code used are in the supplementary appendices. 137 
 138 
2.4 Regression modelling 139 
The change in the odds of diagnosis at stages I or II between the two-year time periods was estimated using 140 
multilevel logistic regression models. Parameters to estimate the between-CCG variation in diagnosis at stages I or II 141 
in each time period were fitted and compared using Wald tests. These were also used to estimate odds ratios for 142 
CCGs at the 2.5th, 25th, 75th,  and 97.5th percentiles, to illustrate the differences in early diagnosis odds between 143 
average CCGs and those with highest and lowest percentages of patients diagnosed early. The models were fitted in 144 
STATA using meqrlogit [35]. 145 
The first set of models included only time period and CCG as explanatory variables. A second set of case-mix 146 
adjusted variables were fitted including these variables along with age, sex, CCI, tumour topography, and tumour 147 
morphology.  Further details on the model specification are provided the supplementary appendices. 148 
 149 
3. RESULTS 150 
We analysed cancer registrations of 196,511 colorectal, 180,048 NSCLC, and 29,076 ovarian cancer patients 151 
diagnosed during the period 2008-2013 (Table 1). On average in each time period and in each CCG there were 313, 152 
287, and 46 new diagnoses of colorectal cancer, NSCLC, and ovarian cancer respectively (Appendix Table 1).  153 
 154 
3.1 Descriptive analyses 155 
Amongst patients with stage recorded, the percentage diagnosed at stages I or II increased dramatically over time 156 
for colorectal cancer (from 31.0% in 2008-09 to 45.0% in 2012-13) and NSCLC (from 20.0% to 25.6%), whilst for 157 
ovarian cancer it remained similar (from 33.3% to 32.9%).  158 
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For colorectal cancer lower deprivation, higher Charlson score, diagnosis following screening or GP referral, and non-159 
carcinoma disease morphology were all associated with early-stage diagnosis (Table 1). For NSCLC, factors associated 160 
with early diagnosis included female sex, higher Charlson score, diagnosis following referral from a GP or outpatient 161 
service, tumour origin in the lobe as opposed to main bronchus, and carcinoma morphology. For ovarian cancer early 162 
diagnosis was associated with younger age, lower Charlson score, type I epithelial or non-epithelial disease, and 163 
diagnosis following referral from a GP or outpatient service. For all cancers, receipt of major treatment and elective 164 
admission for treatment were strongly associated with early diagnosis. 165 
Table 1 Numbers of patients and percentage diagnosed at stages I or II by age, sex, diagnosis period, deprivation, 166 
comorbidity, tumour topography, tumour morphology, route to diagnosis, cancer registry, major treatment and 167 
admission method 168 
  Colorectal cancer NSCLC Ovarian cancer 














Total                       
All patients 196,511 40.5 39.2   180,048 23.1 20.1   29,076 33.8 40.7 
Age 
15-39 3,458 37.5 41.8   865 31.4 29.6   1,368 64.3 38.7 
40-49 7,423 33.3 35.3   4,158 18.5 17.9   2,551 50.3 34.5 
50-59 20,763 36.0 33.5   17,099 19.5 14.8   4,905 42.2 33.1 
60-69 50,801 41.7 36.9   46,325 23.2 15.6   7,743 30.2 36.6 
70-79 60,785 42.3 37.4  61,184 24.6 18.7   7,181 25.6 41.4 
80-99 53,281 40.2 46.0  50,417 22.6 27.5   5,328 21.5 55.9 
Sex 
Male 110,042 40.4 38.0   100,176 22.0 19.7       
Female 86,469 40.5 40.7   79,872 24.5 20.5      
Diagnosis period 
2008-2009 63,972 31.0 63.0   57,382 20.0 34.2   9,618 33.3 57.1 
2010-2011 66,113 39.8 39.0  60,103 22.5 18.1   9,863 35.4 45.7 
2012-2013 66,426 45.0 16.4   62,563 25.6 8.9   9,595 32.9 19.0 
Deprivation quintile 
1 (Least 
deprived) 42,040 41.8 39.3   25,083 22.7 21.2   6,109 33.5 39.2 
2 43,913 40.7 38.6   32,024 23.1 20.3   6,465 31.8 39.8 
3 41,033 40.4 39.1   35,995 22.1 20.3   6,228 34.3 42.1 
4 36,972 39.5 39.8   39,872 22.9 19.9   5,560 33.4 41.6 
5 (Most 
deprived) 32,553 39.4 39.2   47,074 24.2 19.2   4,714 36.5 40.8 
Charlson comorbidity Index 
0 156,968 39.9 38.4   123,622 20.7 19.2   24,896 34.5 39.6 
1 18,596 43.1 41.8   28,211 29.0 21.1   2,244 29.6 44.5 
2 11,347 41.3 41.1   13,873 28.1 21.9   1,145 32.3 47.0 
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3+ 9,600 43.4 44.8   14,342 28.1 23.8   791 21.7 52.2 
Topography 
Colon 127,152 39.4 40.5 
Main 
Bronchus 8,953 7.8 18.8 Ovary 28,181 33.3 40.8 
Rectum 69,359 42.2 36.9 Lobe  119,253 28.4 13.9 
Fallopian 
tube 895 46.4 34.7 
Missing    Missing 51,842 10.4 34.4         
Morphology 
Carcinoma 156,743 40.8 36.1 Carcinoma 91,659 26.6 12.4 
Type I 
epithelial 5,350 77.1 28.4 
Non-
carcinoma 19,014 60.6 45.5 
Non-
carcinoma 70,198 17.9 24.1 
Type II 
epithelial 21,066 19.7 39.9 
Missing 20,754 12.8 56.9 Missing 18,191 22.5 43.2 
Non-
epithelial 873 76.7 52.3 
                Missing 1,787 17.2 80.5 
Route to diagnosis  
GP referral 45,760 43.7 37.6   37,907 30.5 18.1   6,319 42.5 39.5 
Two-week 
wait 54,249 41.3 29.7  46,647 24.2 8.5   8,600 38.1 28.5 
Emergency 
presentation 44,631 26.4 42.8  64,131 12.7 26.8   9,008 15.4 49.6 
Inpatient 
elective 7,337 42.6 38.9  2,724 14.6 19.9   366 38.5 43.2 
Other 
outpatient 14,027 44.9 41.5  19,510 36.9 18.8   3,172 45.8 40.8 
Screening 16,557 59.6 32.6            
Unknown 13,950 32.7 75.5  9,129 24.8 42.7   1,611 33.4 58.9 
Registry 
North & York 27,139 41.4 38.4   31,102 25.4 19.7   3,501 33.7 26.7 
Trent 20,082 38.4 52.5  19,096 24.1 22.9   2,806 44.9 55.4 
East Anglia 23,718 39.9 35.1  19,076 20.1 16.2   3,560 25.9 52.6 
Thames 36,843 40.6 50.5  32,892 21.2 24.5   5,768 32.8 43.8 
Oxford 10,360 42.7 48.3  7,987 25.1 24.9   1,657 40.8 44.2 
South & West 31,065 41.5 29.1  23,551 21.1 18.4   4,636 29.1 28.7 
West 
Midlands 21,324 39.7 30.5  18,412 21.9 16.2   3,290 33.6 38.2 
Northwest & 
Mersey 25,980 39.7 33.0  27,932 26.0 18.5   3,858 39.1 41.8 
Major treatment 
Yes  120,096 50.0 35.2   23,804 80.6 11.7   16,353 46.4 29.5 
No 76,415 22.7 45.5   156,244 13.2 21.3   12,723 8.4 55.0 
Treatment admission method** 
Elective 95,933 53.9 34.3   23,334 80.9 11.7   14,967 46.2 29.1 
Non-elective 24,163 33.4 38.7   470 66.8 16.2   1,386 48.1 34.3 
* Of patients with a recorded stage 
** Of patients who received major treatment 
 169 
Overall, stage was not recorded for 39.2%, 20.1%, and 40.7% of colorectal, NSCLC, and ovarian cancer patients 170 
respectively. The percentage of patients missing stage decreased dramatically over time for all three cancers, from 171 
34.2-63.0% in 2008-09 to 8.9-19.0% in 2012-13. As stage recording improved, the prognostic characteristics of 172 
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patients without a recorded stage became less favourable: emergency presentation and pre-existing comorbidities 173 
became more common (Appendix Table 2). 174 
Lack of a recorded stage was more common amongst patients who were very young or old compared to the rest of 175 
the cohort. Pre-diagnosis it was associated with pre-existing comorbidities and the emergency diagnosis. Post-176 
diagnosis it was associated with a lower probability of receiving major treatment, and with non-elective (unplanned) 177 
admission. Lack of recorded stage was also associated with absence of records on tumour topography and 178 
morphology.  179 
 180 
3.2 Temporal changes 181 
Multiple imputation-based estimates indicate large increases in the percentage of colorectal cancer patients 182 
diagnosed at stages I or II nationally, from 32% in 2008-09 to 44% in 2012-13 (compared to 31% to 45% in the 183 
complete case analysis; Figure 1). For NSCLC the stages I or II percentage increased from 19% to 25% (compared to 184 
20% to 26%). For ovarian cancer it rose from 28% to 31% (compared to remaining at 33%). These estimates also 185 
provide evidence of a stage shift from IV to III for colorectal and ovarian cancers: the percentage of stage III tumours 186 
amongst all stages III or IV rose from 37% to 48% for colorectal cancer and from 44% to 59% for ovarian cancer 187 










Figure 1 Distribution of stage at diagnosis in England: comparison of crude results (left) and distribution based on 196 












Table 2 Distribution of stage from multiple imputation estimates, by period and cancer 207 
  2008-2009 2010-2011 2012-2013 
    Colorectal cancer   
Patients diagnosed (N) 63,972 66,113 66,426 
Stage I/II % (95% CI) 31.9 (31.4, 32.5) 38.5 (38.1, 39.0) 43.8 (43.4, 44.3) 
Stage I % (95% CI) 11.3 (10.8, 11.8) 14.6 (14.3, 15.0) 17.7 (17.3, 18.0) 
Stage II % (95% CI) 20.6 (20.0, 21.2) 23.9 (23.5, 24.3) 26.2 (25.8, 26.5) 
Stage III % (95% CI) 24.9 (24.4, 25.5) 26.9 (26.4, 27.3) 26.8 (26.4, 27.1) 
Stage IV % (95% CI) 43.1 (42.5, 43.8) 34.6 (34.1, 35.1) 29.4 (29.0, 29.8) 
  NSCLC 
Patients diagnosed (N) 57,382 60,103 62,563 
Stage I/II % (95% CI) 18.9 (18.5, 19.3) 21.7 (21.3, 22.0) 24.8 (24.5, 25.1) 
Stage I % (95% CI) 12.9 (12.6, 13.2) 13.5 (13.2, 13.7) 16.1 (15.8, 16.4) 
Stage II % (95% CI) 6.0 (5.8, 6.3) 8.2 (8.0, 8.5) 8.7 (8.5, 8.9) 
Stage III % (95% CI) 27.7 (27.2, 28.2) 23.3 (22.9, 23.6) 22.5 (22.1, 22.8) 
Stage IV % (95% CI) 53.4 (52.9, 53.9) 55.1 (54.6, 55.5) 52.7 (52.3, 53.1) 
  Ovarian Cancer 
Patients diagnosed (N) 9,618 9,863 9,595 
Stage I/II % (95% CI) 27.9 (26.7, 29.1) 29.7 (28.7, 30.8) 30.5 (29.5, 31.4) 
Stage I % (95% CI) 21.1 (20.0, 22.2) 22.8 (21.9, 23.8) 23.4 (22.5, 24.3) 
Stage II % (95% CI) 6.8 (6.2, 7.5) 6.9 (6.2, 7.6) 7.0 (6.5, 7.6) 
Stage III % (95% CI) 31.7 (30.2, 33.2) 34.8 (33.6, 36.0) 40.7 (39.6, 41.8) 
Stage IV % (95% CI) 40.4 (39.0, 41.9) 35.5 (34.3, 36.6) 28.8 (27.8, 29.8) 
 208 
For NSCLC, early diagnosis is estimated to have increased between 2008-09 and 2012-13 in both models with and 209 
without case mix adjustment (Table 3, Figure 2). However, it was a smaller increase in the case-mix adjusted model 210 
(OR: 1.26 (95%CI: 1.20, 1.32) compared to 1.40 (95% CI: 1.33, 1.47), Table 3). During 2008-2013 the case mix for 211 
NSCLC shifted towards carcinomas (59.3% by 2012-13 compared to 49.5% in 2008-09, Appendix Table 3)), tumours 212 
originating in a lobe, and patients with pre-existing comorbidities; all characteristics associated with earlier 213 
diagnosis.  214 
By contrast, for ovarian cancer early diagnosis is estimated to have increased in both models, but it was a greater 215 
increase in the model in which case mix is adjusted for (OR: 1.17 (95%CI: 1.05, 1.31) compared to 1.12 (95%CI: 1.02, 216 
1.22)).  217 





Figure 2 Model-based estimates for change in odds of diagnosis at stages I or II, and change in between-CCG 221 




3.3 Geographic inequalities 224 
Geographic inequalities in early diagnosis decreased over time for colorectal cancer and ovarian cancer in models 225 
where case-mix was not considered (both p<0.05, Table 3). Geographic inequalities for NSCLC were smaller than for 226 
the other two cancers in 2008-09, but there is no evidence that they decreased. Case-mix adjustment had little 227 
impact on the magnitude of inequalities, or on changes in inequalities over time. 228 
 229 
Table 3: Multi-level logistic regression results: Odds ratios (OR) for change in geographic inequalities and in 230 
probability of diagnosis at stages I or II during 2008-13  231 
  No case mix adjustment Case mix adjustment done*** 
  2008-09 2010-11 2012-13 2008-09 2010-11 2012-13 
  Colorectal cancer  
OR for difference between time 
periods (95% CI) 
1.00 1.34 (1.26, 1.42) 1.70 (1.61, 1.80) 1.00 1.33 (1.25, 1.40) 1.71 (1.62, 1.80) 
Between-CCG variation (95% CI)*  0.09 (0.06, 0.12) 0.04 (0.03, 0.06) 0.01 (0.01, 0.02) 0.09 (0.07, 0.11) 0.05 (0.03, 0.06) 0.01 (0.01, 0.02) 
P-value for differences in 
between-CCG variability** 
. <0.01 <0.01 . <0.01 <0.01 
OR for CCG at 2.5th percentile in 
period 
0.56 0.67 0.80 0.56 0.66 0.79 
OR for CCG at 97.5th percentile 
in period 
1.77 1.49 1.24 1.79 1.52 1.27 
  NSCLC 
OR for difference between time 
periods (95% CI) 
1.00 1.18 (1.12, 1.24) 1.40 (1.33, 1.47) 1.00 1.10 (1.05, 1.16) 1.26 (1.20, 1.32) 
Between-CCG variation (95% CI)*  0.04 (0.03, 0.06) 0.04 (0.03, 0.05) 0.03 (0.02, 0.05) 0.04 (0.03, 0.05) 0.03 (0.02, 0.05) 0.03 (0.02, 0.04) 
P-value for differences in 
between-CCG variability** 
. 0.84 0.61 . 0.76 0.68 
OR for CCG at 2.5th percentile in 
period 
0.68 0.69 0.70 0.69 0.70 0.70 
OR for CCG at 97.5th percentile 
in period 
1.46 1.45 1.43 1.45 1.42 1.42 
  Ovarian cancer 
OR for difference between time 
periods (95% CI) 
1.00 1.08 (0.98, 1.18) 1.12 (1.02, 1.23) 1.00 1.14 (1.02, 1.28) 1.18 (1.05, 1.31) 
Between-CCG variation (95% CI)*  0.10 (0.06, 0.17) 0.04 (0.01, 0.10) 0.04 (0.02, 0.09) 0.13 (0.08, 0.23) 0.05 (0.02, 0.13) 0.05 (0.02, 0.12) 
P-value for differences in 
between-CCG variability** 
. 0.03 0.04 . 0.05 0.04 
OR for CCG at 2.5th percentile in 
period 
0.53 0.69 0.67 0.49 0.65 0.66 
OR for CCG at 97.5th percentile 
in period 
1.87 1.45 1.5 2.05 1.55 1.52 
* Estimated between CCG-variance on log scale 
** Comparing between-CCG variation between 2008-09 and 2010-11; and variability between 2008-09 and 2012-13 






In 2008-09, patients in CCGs with the lowest percentages of patients diagnosed early had 30-50% lower odds of early 235 
diagnosis compared to patients in an average CCG, even after adjustment for case mix (Table 3). By 2012-13 the gap 236 
had reduced to 20-30%. For colorectal cancer the reduction in CCG inequalities equate to an approximate between-237 
CCG range in diagnosis at stages I or II of 21-46% in 2008-09, reducing to 38-50% in 2012-13 (Table 2, Table 3). For 238 
ovarian cancer they equate to a range of 16-44% in 2008-09 reducing to 22-40% in 2012-13 239 
 240 
4. DISCUSSION 241 
We report evidence for substantial increases in the percentage of patients diagnosed early in England during 2008-242 
2013. Geographic inequalities in early diagnosis between CCGs were present in all time periods, but reduced 243 
substantially during 2008-2013 for colorectal cancer and ovarian cancer. Case-mix differences did not account for 244 
the changes we observed. 245 
 246 
4.1 Strengths  247 
We used multiple imputation – a gold-standard approach to minimise bias in cases where a fraction of data is 248 
irretrievably missing - in estimates of national changes in stage at diagnosis [19, 20]. 249 
The patients missing stage data had poorer outcomes [16, 17], were older, had more comorbidities, were more 250 
commonly diagnosed as an emergency, and less likely to receive major treatment. We estimate that excluding them 251 
leads to overstatement of early-stage diagnosis by 1-5 percentage points. For colorectal cancer and NSCLC estimates 252 
of improvements were similar whether or not patients missing stage were included, but for ovarian cancer their 253 
exclusion lead to a different conclusion of no improvement. This finding shows that patients missing recorded stage 254 
need to be considered when evaluating progress in early-stage diagnosis, to avoid bias. 255 
We also found that emergency presentation became more common amongst patients missing stage during 2008-256 
2013, whilst nationally it became less common. This indicates that the increase in stage recording has been skewed 257 
towards patients with better prognostic characteristics. If this trend continues surveillance that excludes patients 258 
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missing stage may become less representative of changes in the population, as patients with a recorded stage 259 
become less similar to patients without one. 260 
We were able to exclude case-mix factors as an explanation for improvements over time. The changes in case mix 261 
also provide contextual information: the observed (unadjusted) increases in early diagnosis over time for NSCLC 262 
occurred as the case-mix skewed towards more carcinomas and increased comorbidities (factors associated with 263 
earlier diagnosis; comorbidities potentially due to incidental detection during X-ray for another condition), whilst for 264 
ovarian cancer early diagnosis increased despite a shift towards increased comorbidities and type II epithelial disease 265 
(factors associated with later diagnosis).  266 
 267 
4.2 Limitations  268 
We imputed missing stage information by assuming that it is missing randomly conditional on all the other 269 
information available, including on patient’s subsequent survival (“missing at random”, MAR). It is likely that this 270 
assumption is not entirely met, and that our approach reduced but did not eliminate bias. More work is needed to 271 
understand the mechanisms for missing data in England and evaluate how bias from it can be reduced. For example, 272 
misspecification of the imputation model could affect the magnitude of increases reported. However, given the very 273 
large effect estimates for changes in early diagnosis and geographic inequalities we found it unlikely that residual 274 
bias would change our overall conclusions.  275 
Another restriction of this study is that data after reform of the NHS in 2013 were not available. This reform may 276 
have had a positive or negative impact on early diagnosis. Additionally, from 2010 NHS funding increases were lower 277 
in real terms than in previous years, and failed to keep pace with increases in demand, resulting in the need for 278 
efficiency savings and reductions in per-head spend on cancer by 2011 [36]. Increased waits for GP appointments 279 
and at A&E departments have also been documented [37, 38], and the pressure on these gateway services may have 280 





4.3 Effect of early diagnosis interventions in England 284 
The introduction of FOBT screening and increasing referrals under the two-week wait (TWW) urgent GP referral 285 
route to diagnosis are likely to have played a role in the large increases in early diagnosis for colorectal cancer. 286 
Between 2008-09 and 2012-13 the percentage of patients diagnosed through screening rose from 6% to 10% and 287 
diagnoses through TWW rose from 26% to 30%, corresponding to 2,600 more patients per annum diagnosed 288 
through these routes (Appendix Table 5).  289 
We estimate that by 2012-13 there were almost 4,000 fewer new colorectal cancer diagnoses at stage IV annually 290 
(Table 2), and corresponding increases in diagnoses at stages I, II and, to an extent, III. One concern about screening 291 
programmes is the increased risk of overdiagnosis and corresponding increase in unnecessary treatment of low-292 
grade/benign tumours [39]. If overdiagnosis increases, there be increases in incidence, early diagnosis, and survival 293 
without benefit to patients. Our estimates indicate that early diagnosis increases for colorectal cancer during 2008-294 
2013 are unlikely to be due to increased overdiagnosis. This is because incidence rose only slightly, whilst the 295 
absolute number of diagnoses at stage IV dropped substantially. 296 
For NSCLC and ovarian cancers there were also large increases in 2WW diagnoses in this period. These may have 297 
resulted from the introduction of GP referral guidelines and symptom awareness campaigns. 298 
The changes in early diagnosis during 2008-2013 occurred following sustained government investment in cancer 299 
control initiated through the national Cancer Plan in 2000 (which promised an additional £570 million for cancer by 300 
2003-04) [7]. Though it is probable that the increased spending coupled with this plan (and subsequent extensions to 301 
it in 2007 and 2011 [8, 11]) led to improvements in early-stage diagnosis, empirical data supporting it have thus far 302 
been sparse. Our study provides evidence for a stark improvement. It seems likely that these cancer plans have at 303 
least in part led to this, as well as contributing to reduced geographic inequalities, if national referral guidelines and 304 






4.4 Conclusion and recommendations 309 
We report very large increases in the percentage of patients diagnosed at stages I or II for colorectal cancer and 310 
NSCLC during 2008-2013, and a smaller increase for ovarian cancer. The increases we report may be subject to 311 
residual bias from missing stage data, however the overall conclusion of large improvements is robust to some 312 
misestimation. Increased investment and more frequent diagnoses through screening (for colorectal cancer only) 313 
and the two-week wait route to diagnosis are likely to have contributed to the increases. Geographic inequalities 314 
reduced considerably for colorectal and ovarian cancer over the same time period.  315 
Though useful for rapid surveillance and evaluation of success against government targets, two measures currently 316 
used by Public Health England, the “complete case” early stage percentage and missing stage percentage, give an 317 
incomplete picture of changes in early diagnosis in the population. Epidemiological analyses of stage trends are 318 
needed in addition to these in order to evaluate progress. Patient records missing stage should be included in 319 
surveillance through an imputation approach as done here, or prognostic measures based on estimated stage or 320 
survival could be used [16]. This recommendation is based on analysis of patients in England, but is likely to be 321 
equally relevant to the Detect Cancer Early programme in Scotland [40], and other stage surveillance programmes 322 
internationally. 323 
Our findings are based on a gold-standard approach to reduce bias when stage data are missing but auxiliary 324 
information is available. They concord with improvements in survival during this period [41]. However, further 325 
research is needed to better understand the mechanisms by which stage is missing and to optimise imputation 326 
models; to replicate our finding of a very large increase in colorectal cancer early diagnosis; and to understand the 327 
drivers of improvement. 328 
Our analysis concludes in 2013. It is important that epidemiological analyses of trends in early stage diagnosis after 329 
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SUPPLEMENTARY APPENDIX 436 
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Appendix Table 1 Counts of patients in each diagnosis period by CCG and stage at diagnosis 438 
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Appendix Table 2 Characteristics of the patients without a recorded stage at diagnosis 441 
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Appendix Table 3 Distribution of case-mix characteristics in each time period (with multiple imputation estimates 444 













Count (%) of patients by stage at diagnosis 
2012-2013
Colorectal cancer NSCLC Ovarian cancer
Count of patients by CCG
























6,214 (9.7) 11,247 (17.0) 15,262 (23.0)
10,112 (15.8) 13,028 (19.7) 15,291 (23.0)
2,435 (4.2) 4,219 (7.0) 5,109 (8.2)
2,480 (3.9) 5,970 (9.0) 9,899 (14.9)
4,859 (7.6) 10,052 (15.2) 15,074 (22.7)
19,637 (34.2) 10,873 (18.1) 5,597 (8.9)
1,041 (10.8) 1,472 (14.9)
1,356 (14.1) 1,582 (16.0)
10,893 (19.0) 11,803 (19.6) 12,995 (20.8)
19,301 (33.6) 26,329 (43.8) 29,395 (47.0)
5,116 (8.9) 6,879 (11.4) 9,467 (15.1)
2,048 (21.3)
5,491 (57.1) 4,508 (45.7) 1,821 (19.0)
1,979 (20.6)
333 (3.5) 426 (4.3) 576 (6.0)
1,397 (14.5) 1,875 (19.0) 3,171 (33.0)
2008-2009 2010-2011 2012-2013 2008-2009 2010-2011 2012-2013 2008-2009 2010-2011 2012-2013
Patients missing stage (%) 40,307 (63.0) 25,816 (39.0) 10,900 (16.4) 19,637 (34.2) 10,873 (18.1) 5,597 (8.9) 5,491 (57.1) 4,508 (45.7) 1,821 (19.0)
Average age 72 73 74 75 75 76 68 69 70
Female (%) 45.2 45.5 47.8 44.7 45.6 47.2 - - -
1+ comorbidities (%) 19.2 22.6 29 31.6 36.6 39.9 15 16.8 20.2
Emergency presentation (%) 23.5 24.8 29.6 46.1 48.3 50.9 36.8 37.8 40.7
Deprivation quintile 4/5 (%) 36.1 35.4 34.5 47.8 46.4 45.7 35.5 36.6 34.9
Colorectal cancer NSCLC Ovarian cancer
2008-09 2010-11 2012-13 2008-09 2010-11 2012-13 2008-09 2010-11 2012-13
15-39 (%) 1.5 1.6 2.2 0.5 0.5 0.4 4.8 4.5 4.8
40-49 (%) 3.7 3.7 3.9 2.4 2.3 2.2 8.6 9.1 8.6
50-59 (%) 10.1 10.3 11.2 9.8 9.4 9.2 17.0 16.4 17.2
60-69 (%) 26.4 26.5 24.7 25.2 25.7 26.3 26.2 26.6 27.1
70-79 (%) 31.3 31.0 30.5 34.3 33.7 34.0 24.8 24.7 24.6
80-99 (%) 27.1 26.8 27.4 27.8 28.4 27.9 18.6 18.7 17.6
Male (%) 55.7 56.0 56.3 56.5 55.8 54.7
Female (%) 44.3 44.0 43.7 43.5 44.2 45.3
0 (%) 81.9 80.1 77.7 71.7 68.6 65.9 87.0 85.5 84.4
>0 (%) 18.1 19.9 22.3 28.3 31.4 34.1 13.0 14.5 15.6
Colon (%) 64.3 64.6 65.2 Main bronchus 9.0 7.6 6.1 Ovary 97.7 97.2 95.8
Rectum (%) 35.7 35.4 34.8 Lobe 91.0 92.4 93.9 Fallopian tube 2.3 2.8 4.2
Carcinoma (%) 90.2 89.9 88.2 Carcinoma 49.5 57.1 59.3 Type I epithelial 19.4 18.9 18.9
Non-carcinoma (%) 9.8 10.1 11.8 Non-carcinoma 50.5 42.9 40.7 Type II epithelial 77.2 78.0 78.2










Appendix Table 4 Multi-level logistic regression results: Odds ratios (and 95% CIs) for association between patient 451 












2008-2009 1.00 1.00 1.00
2010-2011 1.33 (1.25, 1.40) 1.10 (1.05, 1.16) 1.14 (1.02, 1.28)
2012-2012 1.71 (1.62, 1.80) 1.26 (1.20, 1.32) 1.18 (1.05, 1.31)
15-39 1.00 1.00 1.00
40-49 0.90 (0.82, 0.98) 0.36 (0.30, 0.43) 0.74 (0.58, 0.93)
50-59 1.02 (0.95, 1.10) 0.35 (0.30, 0.41) 0.61 (0.50, 0.75)
60-69 1.29 (1.20, 1.39) 0.42 (0.35, 0.49) 0.45 (0.37, 0.55)
70-79 1.30 (1.21, 1.39) 0.43 (0.36, 0.50) 0.36 (0.29, 0.44)
80-99 1.05 (0.97, 1.13) 0.40 (0.34, 0.47) 0.27 (0.22, 0.34)
Male 1.00 1.00 NA
Female 1.00 (0.98, 1.02) 1.19 (1.19, 1.19)
0 1.00 1.00 1.00
1 1.06 (1.02, 1.09) 1.55 (1.50, 1.60) 0.93 (0.81, 1.07)
2 0.97 (0.93, 1.01) 1.52 (1.45, 1.59) 1.04 (0.87, 1.23)
3+ 1.06 (1.02, 1.11) 1.55 (1.48, 1.62) 0.69 (0.52, 0.91)
Colon 1.00 Lobe 1.00 Ovary 1.00
Rectum 1.12 (1.10, 1.14) Main Bronchus 0.25 (0.23, 0.28) Fallopian tube 3.37 (2.84, 4.01)
Carcinoma 1.00 Carcinoma 1.00 Type I epithelial 1.00
Non-carcinoma 2.10 (2.03, 2.16) Non-carcinoma 0.60 (0.58, 0.62) Type II epithelial 0.07 (0.07, 0.08)




* Cancer sites are defined by the following ICD codes: Colon=C18; Rectum=C19,C20,C21.8; Main Bronchus=C34.0; 





Route to diagnosis (%) 2008-09 2010-11 2012-13 2008-09 2010-11 2012-13 2008-09 2010-11 2012-13
Emergency presentation 14,743 (23.1) 14,563 (22.0) 15,325 (23.1) 21,230 (37.0) 21,284 (35.4) 21,617 (34.6) 3,133 (32.6) 3,030 (30.7) 2,845 (29.7)
GP referral 15,343 (24.0) 15,120 (22.9) 15,297 (23.0) 12,135 (21.2) 12,326 (20.5) 13,446 (21.5) 2,173 (22.6) 2,077 (21.1) 2,069 (21.6)
Inpatient Elective 2,841 (4.4) 2,322 (3.5) 2,174 (3.3) 937 (1.6) 894 (1.5) 893 (1.4) 161 (1.7) 114 (1.2) 91 (1.0)
Other outpatient 5,135 (8.0) 4,588 (6.9) 4,304 (6.5) 6,050 (10.5) 6,258 (10.4) 7,202 (11.5) 1,156 (12.0) 1,104 (11.2) 912 (9.5)
Screening 3,738 (5.8) 6,415 (9.7) 6,404 (9.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
TWW 16,502 (25.8) 17,981 (27.2) 19,766 (29.8) 13,688 (23.9) 15,340 (25.5) 17,619 (28.2) 2,316 (24.1) 2,874 (29.1) 3,410 (35.5)
Unknown or missing 5,670 (8.9) 5,124 (7.8) 3,156 (4.8) 3,342 (5.8) 4,001 (6.7) 1,786 (2.9) 679 (7.1) 664 (6.7) 268 (2.8)





Appendix: List of OPCS codes used to determine receipt of major surgical treatment. This list was produced by staff 465 







Code Description Code Description Code Description
H011 Emergency excision of abnormal appendix and drainage HFQ H115
Colectomy and exteriorisation of bowel (CODE COLOSTOMY 
SEPERATELY)
Q071
Radical Hysterectomy (removes uterus + cervix + vagina). 
Wertheims hysterectomy
H012 Emergency excision of abnormal appendix NEC H118 Other excision of colon, other specified Q072
Abdominal Hysterectomy and excision of periuterine tissue 
NEC.Radical Hysterectomy 
H013 Emergency excision of normal appendix H119
Hemicolectomy NEC; Colectomy NEC,  Other excision of colon, 
unspecified; 
Q074
TAH, Panhysterectomy, hysterectomy NEC (removes uterus + 
cervix). Total abdominal hysterectomy NEC
H018 Other specified emergency excision of appendix H121 Excision of diverticulum of colon Q221 Bilateral salpingoophorectomy
H019 Emergency appendicectomy NEC, unspecified H122 Polypectomy NEC, Excision of lesion NEC Q223 Bilateral oophorectomy, excision of gonads
H021 Interval appendicectomy H123 Destruction of lesion of colon NEC Q231 Unilateral salpingoophorectomy NEC
H022 Planned delayed appendicectomy NEC H128 Other specified extirpation of lesion of colon Q232
Salpingoophorectomy of remaining solitary fallopian tube and 
ovary
H023 Prophylactic appendicectomy NEC H129 Unspecified extirpation of lesion of colon Q235 Unilateral oophorectomy NEC
H024 Incidental appendicectomy H291
Subtotal excision of colon and rectum and creation of colonic pouch 
and anastomosis of colon to anus
Q241 Salpingoophorectomy NEC
H028 Other specified other excision of appendix H292
Subtotal excision of colon and rectum and creation of colonic pouch 
NEC
Q243 Oophorectomy NEC
H029 Appendicectomy NEC, unspecified; H293
Subtotal excision of colon and creation of colonic pouch and 
anastomosis of colon to rectum
Q431 Excision of wedge of ovary
H041 Proctocolectomy NEC, Panproctocolectomy and Ileostomy H294 Subtotal excision of colon and creation of colonic pouch NEC Q432 Excision of lesion of ovary - cystectomy
H042
Panproctocolectomy and anastomosis of ileum to anus and creation 
of pouch HFQ
H298 Subtotal excision of colon, Other specified Q433 Marsupialisation of lesion of ovary
H043 Panproctocolectomy and anastomosis of ileum to anus NEC H299 Subtotal excision of colon, Unspecified Q439 Unspecified partial excision of ovary
H048 Other specified total excision of colon and rectum H331
Abdominoperineal excision of rectum and end colostomy; APR; 
SCAPER
Q441 Open cauterisation of lesion of ovary
H049
Panproctocolectomy NEC, Total excision of colon and rectum, 
unspecified- 
H332 Proctectomy and anastomosis of colon to anus Q449 Unspecified open destruction of lesion of ovary
H051 Total colectomy and anastomosis of ileum to rectum H333
Anterior resection of rectum and anastomosis of colon to rectum 
using staples
Q478 Other specified other open operations on ovary
H052 Total colectomy and ileostomy and creation of rectal fistula HFQ H334 Anterior resection of rectum and anastomosis NEC Q479 Unspecified other open operations on ovary
H053 Total colectomy and ileostomy NEC H335
Hartmann procedure, Rectosigmoidectomy and closure of rectal 
stump and exteriorisation of bowel (CODE COLOSTOMY SEPERATELY)
Q498 Other specified therapeutic endoscopic operations on ovary
H058 Total excision of colon, other specified H336
Anterior resection of rectum and exteriorisation, (CODE COLOSTOMY 
SEPARATELY)
Q499 Unspecified therapeutic endoscopic operations on ovary
H059 Total excision of colon, Unspecified H337 Perineal resection of rectum HFQ Q518 Other operations on ovary, Other specified
H061 Extended right hemicolectomy and end to end anastomosis H338
Anterior Resection of Rectum NEC, Rectosigmoidectomy and 
anastomosis of colon to rectum Excision of rectum, other specified
Q519 Other operations on ovary, Unspecified
H062 Extended right hemicolectomy and anastomosis of ileum to colon H339 Rectosigmoidectomy NEC, Excision of rectum, unspecified; T361 Omentectomy – Complete
H063 Extended right hemicolectomy and anastomosis NEC H341
Open excision of lesion of rectum: Open removal of polyp; Yorke 
Mason
T865 Para-aortic lymph node sampling 
H064 Extended right hemicolectomy and ileostomy HFQ H342 Open cauterisation of lesion of rectum, Diathermy T868 Pelvic  lymph node sampling 
H068 Other specified extended excision of right hemicolon H343 Open cryotherapy to lesion of rectum T875 Para-aortic lymphadenectomy
H069
Extended excision of Right hemicolon, unspecified, excision of Right 
colon and surrounding tissue
H344 Open laser destruction of lesion of rectum T878 + Z941 Bilateral pelvic lymphadenectomy
H071
Right hemicolectomy and end to end anastomosis of ileum to colon, 
Ileocaecal resection
H345 Open destruction of lesion of rectum NEC T878 + Z942 Right pelvic lymphadenectomy
H072
Right hemicolectomy and side to side anastomosis of ileum to 
transverse colon, 
H348 Open removal of lesion of rectum, other specified T878 + Z943 Left pelvic lymphadenectomy
H073 Right hemicolectomy and anastomosis NEC H349 Open removal of lesion of rectum, unspecified X141 Total exenteration of pelvis
H074 Right hemicolectomy and ileostomy HFQ H401 Trans-sphincteric excision of mucosa of rectum X142 Anterior exenteration of pelvis
H078 Other specified other excision of right hemicolon H402 Trans-sphincteric excision of lesion of rectum X143 Posterior exenteration of pelvis
H079
Other excision of right hemicolon, unspecified; Right hemicolectomy 
NEC
H403 Trans-sphincteric destruction of lesion of rectum X148 Clearance of Pelvis OS
H081 Transverse colectomy and end to end anastomosis H404 Trans-sphincteric anastomosis of colon to anus X149 Clearance of Pelvis unspecified
H082 Transverse colectomy and anastomosis of ileum to colon H408 Other specified operations on rectum through anal sphincter
H083 Transverse colectomy and anastomosis NEC H409 Unspecified operations on rectum through anal sphincter
H084 Transverse colectomy and ileostomy HFQ X141 Total exenteration of pelvis
H085
Transverse colectomy and exteriorisation of bowel NEC (CODE 
COLOSTOMY SPERATELY)
X142 Anterior exenteration of pelvis
H088 Other specified excision of transverse colon X143 Posterior exenteration of pelvis
H089 Excision of transverse colon, unspecified X148 Other specified clearance of pelvis
H091 Left hemicolectomy and end to end anastomosis of colon to rectum X149 Clearance of pelvis, unspecified
H092 Left hemicolectomy and end to end anastomosis of colon to colon
H093 Left hemicolectomy and anastomosis NEC E391 Open excision of lesion of trachea 
H094 Left hemicolectomy and ileostomy HFQ E398 Other specified partial excision of trachea 
H095
Left hemicolectomy and exteriorisation of bowel NEC (CODE 
COLOSTOMY SEPERATELY)
E399 Unspecified partial excision of trachea 
H098 Excision of left hemicolon, Other specified E441 Excision of carina 
H099 Left hemicolectmy NEC, Excision of left hemicolon, Unspecified E461 Sleeve resection of bronchus and anastomosis HFQ 
H101 Sigmoid colectomy and end to end anastomosis of ileum to rectum E541 Total pneumonectomy, total removal of lung, Pneumonectomy NEC 
H102 Sigmoid colectomy and anastomosis of colon to rectum E542 Bilobectomy of lung 
H103 Sigmoid colectomy and anastomosis NEC E543 Lobectomy of lung 
H104 Sigmoid colectomy and ileostomy HFQ E544 Excision of segment of lung 
H105 Sigmoid colectomy and exteriorisation of bowel NEC E545 Partial lobectomy of lung NEC 
H108 Other specified excision of sigmoid colon E548 Excision of lung, other specified 
H109 Unspecified excision of sigmoid colon E549 Excision of lung, Unspecified 
H111 Colectomy and end to end anastomosis of colon to colon NEC E552 Open excision of lesion of lung 
H112 Colectomy and side to side anastomosis of ileum to colon NEC E559 Open removal of lesion of lung, unspecified 
H113 Colectomy and anastomosis NEC T013 Excision of lesion of chest wall 
H114 Colectomy and ileostomy NEC T023 Insertion of prothesis into chest wall NEC 
NSCLC
Ovarian cancerColorectal cancer Colorectal cancer (continued)
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Supplementary Appendix: multiple imputation 473 
Missing stage was imputed on the basis of auxiliary patient information using joint modelling with the R package 474 
jomo (subcommand jomo1rancat) [29], treating stage as a categorical variable with no ordering and accounting for 475 
the multi-level structure of the data.  476 
The modelling assumes that stage is missing randomly conditional on variables that are highly associated with either 477 
stage (I to IV) [1, 2, 30-32] or recording of stage [19]: quarter year of diagnosis, cancer registry area, CCG, age, sex, 478 
patient’s Indices of Multiple deprivation (IMD) income quintile, Charlson comorbidity score [27], tumour topography, 479 
tumour morphology, route to diagnosis, receipt of major treatment (yes/no), major treatment admission method 480 
(elective/non-elective), time from diagnosis to censoring in days, and vital status at censoring.  481 
Information on survival time was included in the imputation model as i) the Nelson Aalen cumulative hazard 482 
estimate ii) a binary indicator for whether censored or died. Three random effects were included, one for CCG in 483 
each of the three time periods (i.e. treated like three independent random intercepts, each estimated from the 484 
subset of patients diagnosed in that time period). Cancer registry, deprivation, charlson score (0, 1, 2, 3+), age group 485 
(15-39, 40-49, 50-59, 60-69, 70-79, 80-99), topography, morphology, route to diagnosis, and quarter year of 486 
diagnosis (Jan-Mar 2008, Apr-Jun 2008, … , Jul-Sep 2013, Oct-Dec 2013) were all included as categorical variables. 487 
For colorectal cancer only the sensitivity of the imputation to the addition of interaction terms (including between 488 
age and time period, and between cumulative hazard and the binary indicator for death) was evaluated. Their 489 
inclusion was not found to materially change the results. 490 
The imputation therefore allowed for differences in the stage distribution between periods as small as three months. 491 
Descriptive analyses using the imputation datasets included estimates of the stage distribution in each of these 492 
three-month periods, whilst the modelling analysis only compared differences between larger two-year time periods 493 
in order to achieve greater power to detect differences between the start and end of 2008-2013.  494 
The number of imputation datasets created was 39, 20, and 41 respectively for colorectal cancer, NSCLC, and ovarian 495 
cancer, chosen to reduce the computational burden whilst achieving minimal power reduction compared to using 496 
n=100 datasets (an estimated reduction of <1% for all cancers [33]). Parameter estimates (percentages of patients at 497 
different stages and regression model parameters) were produced using each dataset and combined using Rubin’s 498 
















Supplementary Appendix: modelling  513 
The analysis models were specified as follows, where 𝑖 denotes a patient, 𝑗 their CCG of residence; 𝑦𝑖𝑗 whether a 514 
patient was diagnosed at stage I or II, 𝑿𝒊𝒋 the vector of patient and tumour covariables, and 𝜇𝑗𝑘  the variance 515 




                                      520 
                                                                                       521 
𝑙𝑜𝑔𝑖𝑡 (Pr(𝑦𝑖𝑗 = 1|𝑿𝒊𝒋, 𝑼𝒋𝒌)) = (𝛽1 + 𝜇𝑗1) + 𝑇2(𝛽2 + 𝜇𝑗2) + 𝑇3(𝛽3 + 𝜇𝑗3) + 𝛽4𝑥4𝑖 + ⋯ + 𝛽𝑛𝑥𝑛𝑖   522 
 523 
𝜇𝑗𝑘  ~ 𝑁(0, 𝜑𝑘
2) 524 
𝑇2 = {
1 𝑖𝑓 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 𝑑𝑎𝑡𝑒 𝑖𝑠 𝑖𝑛 2010 𝑜𝑟 2011;
0  𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
 525 
 𝑇3 = {
1 𝑖𝑓 𝑑𝑖𝑎𝑔𝑛𝑜𝑠𝑖𝑠 𝑑𝑎𝑡𝑒 𝑖𝑠 𝑖𝑛 2012 𝑜𝑟 2013;
0 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
 526 
The models were run once with just the (A) parameters (no case-mix adjustment) then run with both the (A) and (B) 527 
parameters (case-mix adjustment), and results compared. The (B) parameters were specified in the analysis model as 528 
categorical variables, identical to their specification in the imputation model. 529 
The odds ratios exp(𝛽2) and exp(𝛽3) provide information on changes in the probability of diagnosis at stage I/II at 530 
the national level. The total estimated between-CCG variance at each time period (𝜇𝑗1 , 𝜇𝑗2 , 𝜇𝑗3), and the derived 531 
odds ratios for 2.5th , 25th, 75th, and 97.5th percentiles of CCG effects, provide information on geographic inequalities.  532 
The command meqrlogit was used to fit the regression models in STATA, as this command typically has fewer 533 
problems with convergence compared the alternative melogit when estimated random effects are small [4]. The 534 
model estimates distinct CCG effects for each period as separate levels in the model (with no overlap in records used 535 
to estimate effects at different levels), in an analogous specification to the multilevel heterogeneity models used in 536 
longitudinal studies which allow variability in growth curves between boys and girls (e.g. those described in Rabe-537 









(B) Parameters for age group (15-
39, 40-49, 50-59, 60-69, 70-79, 
80-99) sex, Charlson score (0, 1, 
2, 3+), topography, morphology, 
comorbidity 
(A) Parameters for 
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